IFNL3 Gene Testing
The IFNL3 gene is responsible for creating the protein interferon lambda 3. This is an antiviral and anti-proliferative, cytokine that also helps modulate our body’s immune response. Cytokines are consistently released when our bodies deal with infection from both viruses and bacteria. They are also released to handle tumor cells. Genetic variations in the genese responsible for making interferon lambda 3, can affect how a patient will respond to Hepatitis C treatments.
Genetic Variations & Rebetol® and Pegasys® Treatments
Different individuals react differently to Hepatitis C. HCV is one of the most common sexually transmitted infections. Two common treatments for HCV include pegylated interferon-alfa2a (Pegasys) and ribavirin (Rebetol). IFNL3 gene mutations is the greatest genetic predictor on how an individual will respond to these treatments.
Pharmacogentic Testing for HCV Medications
Pharmacogenetic testing is an effective way to predict whether or not a treatment will be effective for a patient. If a patient is about to begin treatment for HCV, it could be valuable for both the patient and the physician to order these tests and determine whether or not this treatment plan will be effective. Patients who have a family history where other family members did not respond positively to HCV treatment should be considered ideal candidates for PGx testing.